Christina Mayerhofer

clinician scientist, postdoc in leukemia chemoresistance

[Cell Metabolism @Cell_Metabolism]

Leveraging induced cell states for cancer therapy: The case for dynamic synthetic lethality dlvr.​it/TWChrj

[Nick van Gastel @nickvangastel]

New preprint from the lab! In this study we dive into the mechanisms that give #leukemia cells #metabolic plasticity, and how it differs from healthy cells. We discovered a process involving rapid changes in protein S-acylation unique to leukemia!
https://t.co/8fSHghghJA

[Daniel Starczynowski @dstarczynowski]

Interested in therapy resistance in blood cancers? Join us at the #ASH25 Scientific Workshop: https://t.co/LQoVtiT5WE

The workshop takes place tomorrow @ 3PM (Friday, Dec 5)! @ASH_hematology

[Cell Metabolism @Cell_Metabolism]

New! Online now: OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis https://t.co/RzCLnGJlO0

[Christina Mayerhofer @ChMayerhofer]

Finally online!

Thrilled to share how AML cells persist under chemo + nutrient stress.
We identify OGFOD1 as a ribosomal dioxygenase that boosts protein synthesis & drives leukemia in vivo. Targeting OGFOD1 improved survival.
https://t.co/hbQoycyUJv
@ScaddenLab @Cell_Metabolism

[Giulia Schiroli @GiuliaSchiroli]

Finally out!
Great collaboration @ScaddenLab @JD_Buenrostro
Epigenetic heterogeneity of the clone of origin shapes phenotypic responses in clonal hematopoiesis - we uncover a Sox4-high state that predisposes Tet2 mutant clones for dominance.
@NatureComms
https://t.co/cL9zXWwn8w